T
Tizona Therapeutics
Transforming cancer treatment with first-in-class immunotherapies driven by novel scientific insights
About Tizona Therapeutics
Tizona Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of innovative immunotherapies for cancer treatment. The company's primary mission is to improve the outcomes for cancer patients by translating groundbreaking scientific insights into first-in-class immunotherapies.
Read full description
Tizona serves a broad range of clients, primarily patients suffering from advanced refractory or resistant malignancies. The company is currently in the clinical trial phase, with a recent initiation of a Phase 1b Expansion Study of their product TTX-080. This indicates that the company is in the process of testing its products for safety and efficacy before they can be approved for commercial use.
The business model of Tizona Therapeutics is centered around research and development. The company invests heavily in scientific research to develop novel immunotherapies. Once these therapies are developed and approved, they will be sold to healthcare providers and patients, generating revenue for the company.
In July 2020, Gilead Sciences secured an exclusive option to acquire Tizona Therapeutics for $300 million, indicating the potential value and promise of the startup's research and product pipeline. The appointment of Christine O’Brien as CEO in September 2020 further strengthens the company's leadership and strategic direction.
In summary, Tizona Therapeutics is a promising biotech startup that aims to revolutionize cancer treatment through the development of innovative immunotherapies. The company's potential for growth and success is evident in its robust research initiatives and strategic partnerships.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- South San Francisco, United States
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 35.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Tizona Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2020 | $300M | $1.2B | Gilead Sciences | — |
| SERIES BOther financing | Mar 2016 | $43M | $172M | InterWest Partners · Lightstone Ventures · Canaan · MPM BioImpact | — |
Growth signals
Latest recorded traffic for Tizona Therapeutics is 1.6K monthly website visits, down 30.4% over the last three months. Tizona Therapeutics's team declined 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
MPM BioImpact
InterWest Partners
Amgen Ventures
Abingworth
Lightstone Ventures
Canaan
Series B and later1 investor entered at this stage
Gilead Sciences
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tizona Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tizona Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.